Balovaptan + Esomeprazole
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autism Spectrum Disorder
Conditions
Autism Spectrum Disorder
Trial Timeline
Nov 19, 2019 → Jan 6, 2020
NCT ID
NCT04156646About Balovaptan + Esomeprazole
Balovaptan + Esomeprazole is a phase 1 stage product being developed by Roche for Autism Spectrum Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04156646. Target conditions include Autism Spectrum Disorder.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04156646 | Phase 1 | Completed |
Competing Products
20 competing products in Autism Spectrum Disorder